Stolbrink, M. and Chinouya, M. J. and Jayasooriya, S. and Nightingale, R. and Evans-Hill, L. and Allan, K. and Allen, H. and Balen, J. and Beacon, T. and Bissell, K. and Chakaya, J. and Chiang, C-y. and Cohen, M. and Devereux, G. and El Sony, A. and Halpin, D. M. G. and Hurst, J. R. and Kiprop, C. and Lawson, A. and Mace, C. and Makhanu, A. and Makokha, P. and Masekela, R. and Meme, H. and Khoo, Ee Ming and Nantanda, R. and Pasternak, S. and Perrin, C. and Reddel, H. and Rylance, S. and Schweikert, P. and Were, C. and Williams, S. and Winders, T. and Yorgancioglu, A. and Marks, G. B. and Mortimer, K. (2022) Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 26 (11). pp. 1023-1032. ISSN 1815-7920, DOI https://doi.org/10.5588/ijtld.22.0270.
Full text not available from this repository.Abstract
BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low-and middle-income countries (LMICs), causing avoidable morbidity and mortality. The Inter-national Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi -stake-holder, collaborative efforts.
| Item Type: | Article |
|---|---|
| Funders: | Wellcome Trust, National Institute for Health Research (NIHR) Clinical Lectureship - MRC DTP Programme at Liverpool School of Tropical Medicine, Liverpool, UK [203919/Z/16/Z] |
| Uncontrolled Keywords: | asthma; COPD; non-communicable dis-ease; chronic respiratory disease; inhalers; essential medicines |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine > Primary Care Medicine Department |
| Depositing User: | Ms Koh Ai Peng |
| Date Deposited: | 05 Aug 2024 08:26 |
| Last Modified: | 05 Aug 2024 08:26 |
| URI: | http://eprints.um.edu.my/id/eprint/46215 |
Actions (login required)
 |
View Item |
